Clinically relevant outcome measures for assessing disease activity, disease control and quality of life impairment in patients with chronic spontaneous urticaria and recurrent angioedemaWeller, Karsten; Zuberbier, Torsten; Maurer, MarcusCurrent Opinion in Allergy and Clinical Immunology: June 2015 - Volume 15 - Issue 3 - p 220–226 doi: 10.1097/ACI.0000000000000163 OUTCOME MEASURES: Edited by Henry Milgrom and Pascal Demoly Buy SDC Abstract Author InformationAuthors Article MetricsMetrics Purpose of review The aim of this review is to highlight the most important, clinically relevant patient-reported outcome (PRO) measures for chronic spontaneous urticaria and recurrent angioedema. Recent findings The use of PROs becomes increasingly important in modern patient-centred medicine. In the past years, several new, validated and reliable tools for the assessment of disease activity, disease control and health-related quality of life impairment of chronic spontaneous urticaria and recurrent angioedema patients have become available. These are required to optimize and standardize clinical trials. In addition, they are of increasing relevance in routine management. The major advantage of their application is that they do not only improve and standardize medical record keeping and care but also release valuable time for the actual physician–patient consultation. A prerequisite for this to work out is, however, that the PROs are well embedded into patient management. Summary The currently available PRO measures can help to better determine the patient's disease status, to aid, document and back treatment decisions as well as to improve the assessment of treatment effects. Linguistically validated versions of the PROs are available for many but not all languages yet. Here, further research is needed to close these gaps. Department of Dermatology and Allergy, Allergie-Centrum-Charité, Charité – Universitätsmedizin Berlin, Berlin, Germany Correspondence to PD Dr. med. Karsten Weller, Department of Dermatology and Allergy, Allergie-Centrum-Charité, Charité – Universitätsmedizin Berlin, Charitéplatz 1, Berlin 10117, Germany. Tel: +49 30 450 518438; fax: +49 30 450 518959; e-mail: firstname.lastname@example.org Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (www.co-allergy.com). Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.